468 related articles for article (PubMed ID: 26581710)
1. TSH receptor antibody titers measured with a third-generation assay did not reflect the activity of Graves' ophthalmopathy in untreated Japanese Graves' disease patients.
Mukasa K; Yoshimura Noh J; Kouzaki A; Ohye H; Kunii Y; Watanabe N; Yoshihara A; Matsumoto M; Suzuki M; Ito K
Endocr J; 2016; 63(2):151-7. PubMed ID: 26581710
[TBL] [Abstract][Full Text] [Related]
2. Role of a new bioassay for thyroid-stimulating antibodies (aequorin TSAb) in Graves' ophthalmopathy.
Hiromatsu Y; Eguchi H; Matsuo Y; Kato T; Tani J; Watanabe S; Teshima Y; Araki N
Endocr J; 2020 Mar; 67(3):347-352. PubMed ID: 31827052
[TBL] [Abstract][Full Text] [Related]
3. Increased TRAb and/or low anti-TPO titers at diagnosis of graves' disease are associated with an increased risk of developing ophthalmopathy after onset.
Lantz M; Planck T; Asman P; Hallengren B
Exp Clin Endocrinol Diabetes; 2014 Feb; 122(2):113-7. PubMed ID: 24554511
[TBL] [Abstract][Full Text] [Related]
4. Clinical Association of Thyroid Stimulating Hormone Receptor Antibody Levels with Disease Severity in the Chronic Inactive Stage of Graves' Orbitopathy.
Woo YJ; Jang SY; Lim TH; Yoon JS
Korean J Ophthalmol; 2015 Aug; 29(4):213-9. PubMed ID: 26240504
[TBL] [Abstract][Full Text] [Related]
5. A novel thyroid stimulating immunoglobulin bioassay is a functional indicator of activity and severity of Graves' orbitopathy.
Lytton SD; Ponto KA; Kanitz M; Matheis N; Kohn LD; Kahaly GJ
J Clin Endocrinol Metab; 2010 May; 95(5):2123-31. PubMed ID: 20237164
[TBL] [Abstract][Full Text] [Related]
6. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.
Subekti I; Boedisantoso A; Moeloek ND; Waspadji S; Mansyur M
Acta Med Indones; 2012 Apr; 44(2):114-21. PubMed ID: 22745141
[TBL] [Abstract][Full Text] [Related]
7. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
[TBL] [Abstract][Full Text] [Related]
8. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
[TBL] [Abstract][Full Text] [Related]
9. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
10. Kinetic analyses of changes in serum TSH receptor antibody values after total thyroidectomy in patients with Graves' disease.
Yoshioka W; Miyauchi A; Ito M; Kudo T; Tamai H; Nishihara E; Kihara M; Miya A; Amino N
Endocr J; 2016; 63(2):179-85. PubMed ID: 26632172
[TBL] [Abstract][Full Text] [Related]
11. Nicotinamide phosphoribosyltransferase leukocyte overexpression in Graves' opthalmopathy.
Sawicka-Gutaj N; Budny B; Zybek-Kocik A; Sowiński J; Ziemnicka K; Waligórska-Stachura J; Ruchała M
Endocrine; 2016 Aug; 53(2):497-504. PubMed ID: 26767650
[TBL] [Abstract][Full Text] [Related]
12. Clinical Implications of Immunoglobulin G4 to Graves' Ophthalmopathy.
Yu SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Thyroid; 2017 Sep; 27(9):1185-1193. PubMed ID: 28805160
[TBL] [Abstract][Full Text] [Related]
13. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
[TBL] [Abstract][Full Text] [Related]
14. TSH-receptor antibodies may prevent bone loss in pre- and postmenopausal women with Graves' disease and Graves' orbitopathy.
Siderova M; Hristozov K; Tsukeva A
Arch Endocrinol Metab; 2018; 62(2):221-226. PubMed ID: 29768627
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic testing for Graves' or non-Graves' hyperthyroidism: A comparison of two thyrotropin receptor antibody immunoassays with thyroid scintigraphy and ultrasonography.
Scappaticcio L; Trimboli P; Keller F; Imperiali M; Piccardo A; Giovanella L
Clin Endocrinol (Oxf); 2020 Feb; 92(2):169-178. PubMed ID: 31742747
[TBL] [Abstract][Full Text] [Related]
16. Childhood Graves' ophthalmopathy: results of a European questionnaire study.
Krassas GE; Segni M; Wiersinga WM
Eur J Endocrinol; 2005 Oct; 153(4):515-21. PubMed ID: 16189172
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
Massart C; Gibassier J; d'Herbomez M
Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of TSH receptor antibodies measurement in patients with Graves' orbitopathy.
Eckstein A; Esser J; Mann K; Schott M
Pediatr Endocrinol Rev; 2010 Mar; 7 Suppl 2():198-203. PubMed ID: 20467363
[TBL] [Abstract][Full Text] [Related]
19. Euthyroid and primarily hypothyroid patients develop milder and significantly more asymmetrical Graves ophthalmopathy.
Eckstein AK; Lösch C; Glowacka D; Schott M; Mann K; Esser J; Morgenthaler NG
Br J Ophthalmol; 2009 Aug; 93(8):1052-6. PubMed ID: 19221109
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of thyroid-stimulating immunoglobulin detection for diagnosing Graves' disease and predictors of responsiveness to methimazole.
Liu K; Fu Y; Li T; Liu S; Chen D; Zhao C; Shi Y; Cai Y; Yang T; Zheng X
Clin Biochem; 2021 Nov; 97():34-40. PubMed ID: 34331946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
